Join
Live feed
·
PRReleasevia Quantisnow
Agenus Inc. logo

Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

ByQuantisnow·Wall Street's wire, on your screen.
AGEN· Agenus Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AGEN (Agenus Inc.) and more on Quantisnow.